CN109320502B - 神经降压肽受体配体 - Google Patents

神经降压肽受体配体 Download PDF

Info

Publication number
CN109320502B
CN109320502B CN201811305966.0A CN201811305966A CN109320502B CN 109320502 B CN109320502 B CN 109320502B CN 201811305966 A CN201811305966 A CN 201811305966A CN 109320502 B CN109320502 B CN 109320502B
Authority
CN
China
Prior art keywords
compound
group
diyl
formula
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201811305966.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN109320502A (zh
Inventor
F·欧斯特坎普
C·斯莫灵
U·莱恩科
C·哈斯
J·翁格威斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3B Pharmaceuticals GmbH
Original Assignee
3B Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3B Pharmaceuticals GmbH filed Critical 3B Pharmaceuticals GmbH
Publication of CN109320502A publication Critical patent/CN109320502A/zh
Application granted granted Critical
Publication of CN109320502B publication Critical patent/CN109320502B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201811305966.0A 2012-12-07 2013-12-06 神经降压肽受体配体 Active CN109320502B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12008208.6A EP2740726A1 (en) 2012-12-07 2012-12-07 Neurotensin receptor ligands
EP12008208.6 2012-12-07
CN201380063364.8A CN104837819B9 (zh) 2012-12-07 2013-12-06 神经降压肽受体配体
PCT/EP2013/003700 WO2014086499A1 (en) 2012-12-07 2013-12-06 Neurotensin receptor ligands

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380063364.8A Division CN104837819B9 (zh) 2012-12-07 2013-12-06 神经降压肽受体配体

Publications (2)

Publication Number Publication Date
CN109320502A CN109320502A (zh) 2019-02-12
CN109320502B true CN109320502B (zh) 2022-06-07

Family

ID=47355771

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811305966.0A Active CN109320502B (zh) 2012-12-07 2013-12-06 神经降压肽受体配体
CN201380063364.8A Active CN104837819B9 (zh) 2012-12-07 2013-12-06 神经降压肽受体配体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380063364.8A Active CN104837819B9 (zh) 2012-12-07 2013-12-06 神经降压肽受体配体

Country Status (20)

Country Link
US (3) US10961199B2 (https=)
EP (3) EP2740726A1 (https=)
JP (2) JP6576828B2 (https=)
KR (1) KR102290803B1 (https=)
CN (2) CN109320502B (https=)
AU (1) AU2013354422B2 (https=)
BR (1) BR112015012530B1 (https=)
CA (1) CA2893605C (https=)
DK (2) DK3712131T3 (https=)
ES (2) ES2795923T3 (https=)
FI (1) FI3712131T3 (https=)
HU (2) HUE061839T2 (https=)
IL (1) IL239080B (https=)
MX (1) MX370354B (https=)
PL (2) PL2928870T3 (https=)
PT (2) PT3712131T (https=)
RU (1) RU2671970C2 (https=)
SG (2) SG11201503880YA (https=)
WO (1) WO2014086499A1 (https=)
ZA (1) ZA201503446B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2954934A1 (en) * 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
EP2954933A1 (en) * 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
CN106794264B (zh) * 2014-06-10 2021-03-23 3B制药有限公司 包含神经降压肽受体配体的缀合物及其用途
CA3006313C (en) 2015-11-24 2020-02-11 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
EP3279197A1 (en) * 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
EP3548515B1 (en) 2016-12-01 2026-01-21 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
CA3053348A1 (en) 2017-02-10 2018-08-16 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
KR102880156B1 (ko) 2017-07-24 2025-11-05 리제너론 파마슈티칼스 인코포레이티드 항cd8 항체 및 이의 용도
CN118406106A (zh) 2019-07-08 2024-07-30 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
CN111875667B (zh) * 2020-07-16 2021-12-21 南方科技大学 有机金属螯合物及其制备方法与应用、探针
KR20230092982A (ko) * 2020-10-22 2023-06-26 니혼 메디피직스 가부시키가이샤 방사성 지르코늄 착체의 제조 방법
JP2024517419A (ja) * 2021-04-23 2024-04-22 フュージョン ファーマシューティカルズ インコーポレイテッド がんの処置のための方法
KR20240007257A (ko) * 2021-05-13 2024-01-16 더 제너럴 하스피탈 코포레이션 알데히드의 생체내 검출을 위한 분자 프로브
WO2022261770A1 (en) * 2021-06-16 2022-12-22 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and folfirinox
EP4355377A4 (en) * 2021-06-16 2025-05-07 Fusion Pharmaceuticals Inc. COMBINATION COMPRISING A NEUROTENSIN RECEPTOR BINDING COMPOUND, GEMCITABINE AND NAB-PACLITAXEL
EP4355317A4 (en) * 2021-06-16 2025-04-30 Fusion Pharmaceuticals Inc. COMBINATION WITH A NEUROTENSIN RECEPTOR BINDING COMPOUND AND NAPOX
WO2023141722A1 (en) * 2022-01-28 2023-08-03 Fusion Pharmaceuticals Inc. Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy
AU2023221977A1 (en) * 2022-02-18 2024-08-15 Full-Life Technologies Hk Limited Compounds and radioligands for targeting neurotensin receptor and uses thereof
WO2023215778A1 (en) * 2022-05-03 2023-11-09 The University Of North Carolina At Chapel Hill Development of ntsr targeted agents for imaging and therapy applications
US12091454B2 (en) 2022-12-28 2024-09-17 Development Center For Biotechnology Humanized anti-human neurotensin receptor 1 antibodies and their uses
WO2025144920A1 (en) * 2023-12-28 2025-07-03 Radionetics Oncology, Inc. Neuropeptide y1 receptor (npy1r) targeted therapeutics and uses thereof
WO2025146126A1 (en) * 2024-01-04 2025-07-10 Full-Life Technologies Hk Limited Preparation method of compounds targeting neurotensin receptor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0477049A1 (fr) * 1990-08-20 1992-03-25 Sanofi Dérivés d'amido-3 pyrazole, procédé pour leur préparation et compositions pharmaceutiques les contenant
CN1108651A (zh) * 1993-10-12 1995-09-20 萨诺费公司 对神经降压素活性的取代1-萘基-3-吡啶甲酰胺，其制备及含有它们的药物组合物
CN1184469A (zh) * 1995-04-11 1998-06-10 萨诺费公司 对神经紧张素受体有活性的1－苯基－3－吡唑甲酰胺类化合物
CN101626787A (zh) * 2007-01-19 2010-01-13 马林克罗特公司 诊断的和治疗的环氧合酶-2结合配体
WO2011156557A3 (en) * 2010-06-11 2012-02-02 Thomas James B Compounds active at the neurotensin receptor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110321A (en) 1976-07-12 1978-08-29 Folkers Karl Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity
US4425269A (en) 1982-06-07 1984-01-10 Merck & Co., Inc. Metabolically protected analogs of neurotensin
US4439359A (en) 1982-07-02 1984-03-27 Merck & Co., Inc. Cyclic octapeptide analogs of neurotensin
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
CA2086453A1 (en) 1992-12-30 1994-07-01 Mcgill University Marker for neurotensin receptor
US5407916A (en) 1993-02-16 1995-04-18 Warner-Lambert Company Neurotensin mimetics as central nervous system agents
WO1995022341A1 (en) 1994-02-18 1995-08-24 Mallinckrodt Medical, Inc. Labelled peptide compounds
US6054557A (en) 1995-04-04 2000-04-25 Advanced Bioconcept (1994) Ltd. Fluorescent peptides
EP0820466A2 (en) 1995-04-04 1998-01-28 Advanced Bioconcept Inc. Fluorescent peptides
AU6352296A (en) 1995-07-20 1997-02-18 Advanced Bioconcept, Inc. Cell sorting with fluorescent peptides
EP0968001B1 (en) 1997-02-03 2003-11-05 Mallinckrodt Inc. Method for the detection and localization of malignant human pancreatic tumours
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
EP1067950B1 (en) 1998-04-10 2008-05-14 Mayo Foundation For Medical Education And Research Neo-tryptophan
CA2374270A1 (en) 1999-06-24 2000-12-28 Ananthachari Srinivasan Labeled neurotensin derivatives
JP2007528854A (ja) * 2003-07-09 2007-10-18 カリフォルニア パシフィック メディカル センター 細胞への物質送達の遠隔検出
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
US8487077B2 (en) * 2008-09-16 2013-07-16 The Regents Of The University Of California Simplified one-pot synthesis of [18F]SFB for radiolabeling
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
EP2374003B1 (en) * 2009-01-07 2015-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment, the prognostic assessment and the detection of breast cancer
EP2454272B1 (en) 2009-07-16 2017-08-23 IASON GmbH Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0477049A1 (fr) * 1990-08-20 1992-03-25 Sanofi Dérivés d'amido-3 pyrazole, procédé pour leur préparation et compositions pharmaceutiques les contenant
CN1108651A (zh) * 1993-10-12 1995-09-20 萨诺费公司 对神经降压素活性的取代1-萘基-3-吡啶甲酰胺，其制备及含有它们的药物组合物
CN1184469A (zh) * 1995-04-11 1998-06-10 萨诺费公司 对神经紧张素受体有活性的1－苯基－3－吡唑甲酰胺类化合物
CN101626787A (zh) * 2007-01-19 2010-01-13 马林克罗特公司 诊断的和治疗的环氧合酶-2结合配体
WO2011156557A3 (en) * 2010-06-11 2012-02-02 Thomas James B Compounds active at the neurotensin receptor

Also Published As

Publication number Publication date
KR102290803B1 (ko) 2021-08-18
EP3712131B1 (en) 2023-02-01
HUE050388T2 (hu) 2020-11-30
HUE061839T2 (hu) 2023-08-28
JP2019218375A (ja) 2019-12-26
JP2016501238A (ja) 2016-01-18
WO2014086499A8 (en) 2014-12-31
MX2015007193A (es) 2016-03-17
KR20150092300A (ko) 2015-08-12
RU2015127086A (ru) 2017-01-11
SG11201503880YA (en) 2015-06-29
US10961199B2 (en) 2021-03-30
EP2928870A1 (en) 2015-10-14
JP6576828B2 (ja) 2019-09-18
CA2893605C (en) 2021-08-10
CA2893605A1 (en) 2014-06-12
CN104837819B9 (zh) 2019-07-09
PT3712131T (pt) 2023-04-04
DK3712131T3 (da) 2023-03-20
IL239080B (en) 2019-06-30
RU2671970C2 (ru) 2018-11-08
MX370354B (es) 2019-12-10
BR112015012530A2 (pt) 2017-09-12
EP2740726A1 (en) 2014-06-11
US20150299133A1 (en) 2015-10-22
SG10201704564QA (en) 2017-07-28
JP7042776B2 (ja) 2022-03-28
US20210087149A1 (en) 2021-03-25
ES2795923T3 (es) 2020-11-25
ZA201503446B (en) 2016-01-27
EP2928870B1 (en) 2020-04-08
CN104837819A (zh) 2015-08-12
FI3712131T3 (fi) 2023-03-28
BR112015012530B1 (pt) 2022-07-19
PL3712131T3 (pl) 2023-05-02
DK2928870T3 (da) 2020-07-13
AU2013354422B2 (en) 2018-03-15
CN109320502A (zh) 2019-02-12
AU2013354422A1 (en) 2015-05-28
WO2014086499A1 (en) 2014-06-12
US20260078095A1 (en) 2026-03-19
CN104837819B (zh) 2018-12-07
PL2928870T3 (pl) 2020-09-21
IL239080A0 (en) 2015-07-30
HK1210148A1 (en) 2016-04-15
ES2941629T3 (es) 2023-05-24
PT2928870T (pt) 2020-05-29
EP3712131A1 (en) 2020-09-23

Similar Documents

Publication Publication Date Title
CN109320502B (zh) 神经降压肽受体配体
US20240180856A1 (en) Compositions, delivery systems, and methods useful in tumor therapy
Abd-Elgaliel et al. Design, synthesis, and biological evaluation of an antagonist− Bombesin analogue as targeting vector
JP2024542966A (ja) 胃抑制ペプチドレセプターリガンド
Yan et al. Synthesis and preclinical evaluation of a heterodimeric radioligand targeting fibroblast activation protein and integrin-αvβ3
US20110250133A1 (en) Gastrin releasing peptide compounds
KR20250016195A (ko) 전립선-특이적 막 항원(psma) 리간드
Zoghi et al. Preclinical evaluation of new GnRH‐I receptor radionuclide therapy with 177Lu‐peptide tracer
HK40003630B (en) Neurotensin receptor ligands
HK40003630A (en) Neurotensin receptor ligands
HK40037865B (en) Neurotensin receptor ligands
HK40037865A (en) Neurotensin receptor ligands
HK1210148B (en) Neurotensin receptor ligands
US20250303005A1 (en) Prostate specific membrane antigen (psma) ligands with improved renal clearance
CN121013861A (zh) 具有生物分布调节剂的抑胃肽受体配体
Mascarin Triazole-Based Radiopeptidomimetics: Novel Neurotensin (8-13) Analogues with Increased Metabolic Stability
HK1238553A1 (en) Conjugate comprising a neurotensin receptor ligand and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40003630

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant